Mortality rates of people starting HIV treatment in four African countries approach those of the general population over time, provided that treatment is started before the immune system has been severely damaged, according to research published this week in the open-access journal PLoS Medicine.
In sub-Saharan Africa more than 2 million people with HIV now receive antiretroviral treatment (ART), and mortality in HIV-infected patients who have access to ART is declining. In the new study, Matthias Egger of the University of Berne and colleagues investigated how mortality among HIV-infected people starting ART compares with non-HIV related mortality in Cote d'Ivoire, Malawi, South Africa, and Zimbabwe. The researchers analyzed information about people during their first two years on ART in five treatment programs participating in the International epidemiological Databases to Evaluate AIDS (IeDEA) initiative, and obtained estimates of HIV-unrelated deaths in these countries from the World Health Organization Global Burden of Disease (GBD) project.
Their findings indicate that mortality among HIV-infected people during the first two years of ART is higher than in the general population in these four sub-Saharan countries. However, for patients who start ART when they have a high CD4 lymphocyte count and no signs of advanced HIV disease, the excess mortality is moderate and similar to that associated with diabetes.
Funding: This study was supported by the Office of AIDS Research (OAR) of the National Institutes of Health, the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS), and the National Institute of Allergy and Infectious Diseases (NIAID, grant 1 U01 AI069924-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Citation: Brinkhof MWG, Boulle A, Weigel R, Messou E, Mathers C, et al. (2009) Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Med 6(4): e1000066. doi:10.1371/journal.pmed.1000066
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000066
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-04-egger.pdf
READ THE EDITORS' SUMMARY OF THE PAPER: http://www.plos.org/press/plme-06-04-egger-summary.pdf
CONTACT:
Matthias Egger
University of Berne
Institut fuer Sozial- und Praeventivmedizin
Finkenhubelweg 11
Bern, Bern 3012
Switzerland
+41 31 631 3501
+41 31 631 3520 (fax)
egger@ispm.unibe.ch
Journal
PLoS Medicine